Saturday 17 October 2026
Export OCS’s income statement to Excel — free account
Oculis Holding AG
Oculis Holding AG’s revenue for fiscal 2025 (year ended December 2025) was $1.4 million, up 85.7% from fiscal 2024. In the quarter to June 2026, revenue grew 24.0%, EPS grew 66.1%, free cash flow fell 10.4% and total debt rose 159.8%, each against the same quarter a year earlier.
7.29
0.11
−1.49%
Follow OCS
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 9.59 | 9.66 | 6.26 | 10.11 | 14.00 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 10.48 | 10.50 | 14.50 | 18.00 | 23.08 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | 32 | 28 | 36 | 49 | 60 | ||||
| Revenue/emp, $m | — | — | — | — | — | 0.03 | 0.03 | 0.03 | 0.02 | 0.02 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | 1 | 1 | 1 | 1 | 1 | ||||
| Gross margin, % | — | — | — | — | — | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | |||||
| EBT | — | — | — | — | — | (20) | (40) | (99) | (98) | (120) | |||||
| EBT margin, % | — | — | — | — | — | (1,929.65) | (4,237.10) | (10,044.47) | (12,527.70) | (8,268.77) | |||||
| Net income | — | — | — | — | — | (20) | (40) | (99) | (98) | (120) | |||||
| Depreciation | — | — | — | — | — | 0 | 0 | 0 | 0 | 1 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | 0.38 | 0.32 | 0.03 | 0.02 | 0.03 | ||||
| Earnings | — | — | — | — | — | (7.31) | (13.57) | (3.31) | (2.41) | (2.28) | |||||
| Cash flow | — | — | — | — | — | (5.44) | (8.79) | (2.01) | (1.34) | (1.53) | |||||
| Capex | — | — | — | — | — | (0.01) | (1.24) | 0.00 | (0.01) | (0.03) | |||||
| Free cash flow | — | — | — | — | — | (5.46) | (10.03) | (2.01) | (1.34) | (1.56) | |||||
| Book value | — | — | — | — | — | (24.01) | (34.35) | 3.49 | 2.06 | 4.53 | |||||
| Shares, m | — | — | — | — | — | 3 | 3 | 30 | 40 | 52 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | 107.67 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| P/S | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 881.46 | 720.95 | |||||
| P/B | — | — | — | — | — | 0.00 | 0.00 | 3.36 | 8.24 | 4.41 | |||||
| EV/Sales | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 739.37 | 545.04 | |||||
| EV/FCF | — | — | — | — | — | (14.97) | (2.80) | (3.63) | (10.62) | (9.65) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | (15) | (26) | (60) | (54) | (80) | ||||
| Capex | — | — | — | — | — | 0 | (4) | 0 | 0 | (2) | |||||
| Free cash flow | — | — | — | — | — | (15) | (30) | (60) | (54) | (82) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | 48 | 12 | 91 | 69 | 220 | ||||
| Total debt | — | — | — | — | — | 125 | 129 | 1 | 1 | 2 | |||||
| Net debt | — | — | — | — | — | 74 | 108 | (101) | (111) | (255) | |||||
| Shareholders’ equity | — | — | — | — | — | (67) | (103) | 104 | 83 | 237 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | 0.00 | (79.25) | (119.02) | (73.79) | (56.67) | ||||
| ROIC | — | — | — | — | — | (120.78) | (391.93) | (1,747.97) | 0.00 | 0.00 | |||||
| ROE | — | — | — | — | — | 0.00 | 47.88 | (11,509.96) | (103.79) | (74.65) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
Oculis Holding AG vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| RGNX REGENXBIO Inc. | $472.7M | — (loss-making) | — (loss-making) | +405.73% (above 0%: growing) | n/m | −26.67% (below 0%: shrinking) | 99.04% | 27.09% | Compare |
| ARVN Arvinas, Inc. | $468.2M | 53.6× | — (loss-making) | +1,014.73% (above 0%: growing) | n/m | +49.79% (above 0%: growing) | 96.40% | 65.72% | Compare |
| CBIO Crescent Biopharma, Inc. | $463.6M | — (loss-making) | — (loss-making) | +1,038,900.00% (above 0%: growing) | n/m | −7.04% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| ALLO Allogene Therapeutics, Inc. | $463.0M | — (loss-making) | — (loss-making) | +20,990.91% (above 0%: growing) | n/m | +17.73% (above 0%: growing) | 100.00% | (1,011.21%) | Compare |
| ALT Altimmune, Inc. | $459.1M | — (loss-making) | — (loss-making) | +520.00% (above 0%: growing) | n/m | −25.27% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| AUTL Autolus Therapeutics PLC Sponsored ADR | $457.8M | — (loss-making) | — (loss-making) | +118.37% (above 0%: growing) | n/m | +67.55% (above 0%: growing) | 55.20% | (95.95%) | Compare |
| OCS Oculis Holding AG | $456.8M | — (loss-making) | — (loss-making) | +23.96% (above 0%: growing) | n/m | −10.40% (below 0%: shrinking) | 100.00% | (7,603.42%) | |
| EPRX Eupraxia Pharmaceuticals Inc. | $446.2M | — (loss-making) | — | — | n/m | −56.41% (below 0%: shrinking) | — | 0.00% | Compare |
| MPLT MapLight Therapeutics, Inc. | $445.7M | — (loss-making) | — | — | n/m | −31.91% (below 0%: shrinking) | — | 0.00% | Compare |
| Median of peers | $461.0M | — | — | +767.37% | — | −16.15% | 99.52% | 0.00% |
Oculis Holding AG (OCS) key facts
- Strength: Oculis Holding AG’s revenue for fiscal 2025 (year ended December 2025) was $1.4 million, up 85.7% from fiscal 2024.
- Oculis Holding AG (OCS) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, OCS traded at $7.29, a market capitalization of $456.8 million.
- Return on equity was −74.7% and debt-to-equity 0.01.
- Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 10.51 (safe zone) for fiscal 2025.